Literature DB >> 1802923

Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study.

C Marcocci1, L Bartalena, F Bogazzi, G Bruno-Bossio, A Lepri, A Pinchera.   

Abstract

We have carried out a prospective study to investigate whether orbital radiotherapy combined with high dose systemic glucocorticoids is more effective than orbital radiotherapy alone for Graves' ophthalmopathy. Thirty consecutive patients with relevant and active Graves' ophthalmopathy were randomly assigned to treatment either with orbital radiotherapy combined with systemic glucocorticoids (Group 1, n = 15) or with orbital radiotherapy alone (Group 2, n = 15). The final evaluation was made 6-9 months after beginning treatment. Two patients in each group were lost to follow-up. Ocular involvement and response to treatment were evaluated by the ophthalmopathy index and by clinical assessment. Mean ophthalmopathy index values were 5.85 in Group 1 and 5.46 in Group 2 (p = NS) before treatment, and 2.46 in Group 1 and 3.61 in Group 2 after treatment (p = 0.0001 and p = 0.003 vs initial value, respectively). The mean ophthalmopathy index decrease in Group 1 (-3.39) was significantly greater (p = 0.043) than that in Group 2 (-1.85). Favorable responses on clinical ground occurred in 9 patients (69%) in Group 1 and in 5 patients (38%) in Group 2. The difference was particularly evident on soft tissue changes and extraocular muscle involvement. Severe eye muscle restriction was substantially unaffected by either treatment. In conclusion, the association of orbital irradiation and high dose systemic glucocorticoids in the treatment of severe Graves' ophthalmopathy provides more favorable responses than orbital radiotherapy alone.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1802923     DOI: 10.1007/BF03347943

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  17 in total

1.  Adrenal steroid therapy of severe infiltrative ophthalmopathy of Graves' disease.

Authors:  J BROWN; J W COBURN; R A WIGOD; J M HISS; J T DOWLING
Journal:  Am J Med       Date:  1963-06       Impact factor: 4.965

2.  Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism.

Authors:  L Bartalena; C Marcocci; F Bogazzi; M Panicucci; A Lepri; A Pinchera
Journal:  N Engl J Med       Date:  1989-11-16       Impact factor: 91.245

3.  Prednisone in emergency treatment of malignant exophthalmos.

Authors:  S C Werner
Journal:  Lancet       Date:  1966-05-07       Impact factor: 79.321

4.  Supervoltage orbital radiotherapy for Graves' ophthalmopathy.

Authors:  S S Donaldson; M A Bagshaw; J P Kriss
Journal:  J Clin Endocrinol Metab       Date:  1973-08       Impact factor: 5.958

Review 5.  Diagnostic evaluation of Graves' ophthalmopathy.

Authors:  R S Bahn; J A Garrity; G B Bartley; C A Gorman
Journal:  Endocrinol Metab Clin North Am       Date:  1988-09       Impact factor: 4.741

Review 6.  Endocrine ophthalmopathy: current ideas concerning etiology, pathogenesis, and treatment.

Authors:  D H Jacobson; C A Gorman
Journal:  Endocr Rev       Date:  1984       Impact factor: 19.871

7.  Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study.

Authors:  G Kahaly; J Schrezenmeir; U Krause; B Schweikert; S Meuer; W Muller; R Dennebaum; J Beyer
Journal:  Eur J Clin Invest       Date:  1986-10       Impact factor: 4.686

8.  Radiation therapy for Graves' disease.

Authors:  M W Brennan; C R Leone; L Janaki
Journal:  Am J Ophthalmol       Date:  1983-08       Impact factor: 5.258

9.  Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach.

Authors:  M P Mourits; L Koornneef; W M Wiersinga; M F Prummel; A Berghout; R van der Gaag
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

10.  Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone.

Authors:  L Bartalena; C Marcocci; L Chiovato; M Laddaga; G Lepri; D Andreani; G Cavallacci; L Baschieri; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

View more
  26 in total

Review 1.  Pharmacological treatments for thyroid eye disease.

Authors:  Sara P Modjtahedi; Bobeck S Modjtahedi; Ahmad M Mansury; Dinesh Selva; Raymond S Douglas; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

3.  Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.

Authors:  E Sisti; F Menconi; M Leo; M A Profilo; T Mautone; B Mazzi; R Rocchi; F Latrofa; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2015-01-18       Impact factor: 4.256

Review 4.  The evaluation and treatment of graves ophthalmopathy.

Authors:  Marius N Stan; James A Garrity; Rebecca S Bahn
Journal:  Med Clin North Am       Date:  2012-02-22       Impact factor: 5.456

Review 5.  Graves' orbitopathy: imperfect treatments for a rare disease.

Authors:  Luigi Bartalena
Journal:  Eur Thyroid J       Date:  2013-11-20

6.  Natural history of graves' orbitopathy after treatment.

Authors:  Francesca Menconi; Marenza Leo; Elena Sabini; Teresa Mautone; Marco Nardi; Aldo Sainato; Stefano Sellari-Franceschini; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Endocrine       Date:  2016-10-05       Impact factor: 3.633

7.  Radiotherapy in the treatment of Graves ophthalmopathy-to do it or not?

Authors:  Aneta Zygulska
Journal:  J Ocul Biol Dis Infor       Date:  2009-10-06

8.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Kostas Boboridis; Anja Eckstein; George J Kahaly; Claudio Marcocci; Petros Perros; Mario Salvi; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2016-03-02

9.  A retrospective study on the efficacy of total absorbed orbital doses of 12, 16 and 20 Gy combined with systemic steroid treatment in patients with Graves' orbitopathy.

Authors:  Kristian T M Johnson; Andrea Wittig; Christian Loesch; Joachim Esser; Werner Sauerwein; Anja K Eckstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-10-29       Impact factor: 3.117

10.  Update on thyroid eye disease and management.

Authors:  Erick D Bothun; Ryan A Scheurer; Andrew R Harrison; Michael S Lee
Journal:  Clin Ophthalmol       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.